DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV).
It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions.
It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 192.5K |
| Three Month Average Volume | 32.3M |
| High Low | |
| Fifty-Two Week High | 2.3399 USD |
| Fifty-Two Week Low | 0.007 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 16 Aug 2024 |
| Price and Volume | |
| Current Price | 0.0214 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -64.92% |
| Thirteen Week Relative Price Change | -93.66% |
| Twenty-Six Week Relative Price Change | -97.76% |
| Fifty-Two Week Relative Price Change | -99.26% |
| Year-to-Date Relative Price Change | -98.97% |
| Price Change | |
| One Day Price Change | -41.37% |
| Thirteen Week Price Change | -93.21% |
| Twenty-Six Week Price Change | -97.54% |
| Five Day Price Change | -17.69% |
| Fifty-Two Week Price Change | -99.07% |
| Year-to-Date Price Change | -98.78% |
| Month-to-Date Price Change | -61.79% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.65606 USD |
| Book Value Per Share (Most Recent Quarter) | 1.1439 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.65606 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.1439 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.68408 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.46861 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.46523 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.0908 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.68531 USD |
| Normalized (Last Fiscal Year) | -3.09135 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.0908 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.68531 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.0908 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.68531 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.61809 USD |
| Cash Per Share (Most Recent Quarter) | 1.11486 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.03492 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.60709 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.14481 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -461 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -572.19% |
| Pretax Margin (Last Fiscal Year) | -659.57% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 1.80% |
| Gross Margin (Trailing Twelve Months) | 8.51% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -678.21% |
| Operating Margin (Trailing Twelve Months) | -588.62% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -659.57% |
| Net Profit Margin (Trailing Twelve Months) | -572.19% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 10.58% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 9.71% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 37.49% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 43.66% |
| EPS Change (Trailing Twelve Months) | 31.14% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -38,928,000 |
| Net Debt (Last Fiscal Year) | -55,809,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 152 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 152 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 3 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -77,881,000 |
| Free Cash Flow (Trailing Twelve Months) | -72,215,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -62.28% |
| Return on Assets (Trailing Twelve Months) | -64.00% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -106.46% |
| Return on Equity (Trailing Twelve Months) | -121.75% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -68.42% |
| Return on Investment (Trailing Twelve Months) | -71.29% |
| Return on Investment (5 Year) | -99,999.99% |